title: Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer.
abstract: OBJECTIVE
  We aimed to investigate the prognostic value of biomarkers [Ki-67, adenosine triphosphate-binding cassette sub-family B member 1 (ABCB1), adenosine triphosphate-binding cassette sub-family C member 1 (ABCC1), adenosine triphosphate-binding cassette sub-family C member 2 (ABCC2), p53, cyclin E and v-akt murine thymoma viral oncogene homolog 2 (AKT2)] in patients with advanced epithelial ovarian cancer (EOC).
  
  
  METHODS
  The levels of expression of biomarkers in tumor tissues of 47 patients with stage 3 or 4 EOC were estimated via immunohistochemical staining using tissue microarrays. The associations of biomarker expression with progression-free survival (PFS) and overall survival (OS) were evaluated using a log-rank test and Cox regression analysis.
  
  
  RESULTS
  Based on multivariate analysis, high expression of Ki-67 (p=0.003) and low expression of ABCC2 (p=0.048) were associated with a prolonged PFS. However, other biomarkers were not associated with PFS. Residual tumor <1 cm (p=0.023) and PFS >6 months (p=0.005) were associated with prolonged OS. However, none of the biomarkers were associated with OS.
  
  
  CONCLUSIONS
  High expression of Ki-67 and low expression of ABCC2 appear to be useful as markers for prolonged PFS in patients with advanced EOC.
authors.affiliation: Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Gyeonggi-Do, Republic of Korea.
authors.forename: Haeryoung
authors.initials: H
authors.lastname: Kim
authors.forename: Kidong
authors.initials: K
authors.lastname: Kim
authors.forename: Jae Hong
authors.initials: JH
authors.lastname: No
authors.forename: Yong-Tark
authors.initials: YT
authors.lastname: Jeon
authors.forename: Hye Won
authors.initials: HW
authors.lastname: Jeon
authors.forename: Yong-Beom
authors.initials: YB
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D016190:Carboplatin / Q000008:administration & dosage; D000077216:Carcinoma, Ovarian Epithelial; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D000089762:Multidrug Resistance-Associated Protein 2; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000378:metabolism* / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage; D015996:Survival Rate
chemical_list: C000715087:ABCC2 protein, human; D014408:Biomarkers, Tumor; D000089762:Multidrug Resistance-Associated Protein 2; D016190:Carboplatin; D017239:Paclitaxel